DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

 

Whether positioning a drug effectively for a trial, launch, or market expansion, the risk of an inaccurate or incomplete view of patient cohorts has far-reaching implications.

Download the
Full Viewpoint – With Case Study!

Pharmaceutical teams are acutely aware that sub-populations vary greatly by disease-specific and environment factors, behaviors, treatment pathways and a host of other attributes.

The challenge is to determine how many significant patient sub-populations are present within a single disease, and which populations can be most effectively reached, using what approach.

Often, there are more significant variations between patient subpopulations than pharmaceutical teams initially suspect.

 

Reframing the Approach to Patient Segmentation

Two critical trends have converged to make advanced segmentation both necessary and possible:

Treatment decisions are informed by many other factors than just diagnosis. Pharmaceutical teams also need to take into account the impact of patients’ cost burden, access issues, demographics, co-morbidities, emotional state, compliance issues, challenges with site of care, and much more.

And all the while, markets are shifting all around us. Patient segments are always moving. Every disease area has nuances to consider.

So how can a pharmaceutical team achieve a higher degree of clarity and confidence in their market assessments?

 

Building a More Complete View of Your Patients

The best commercial planning starts with understanding the range of real-world and traditional data sources you might use for advanced segmentation:

 

Tailoring Your Segmentation Strategy:

Examples of How to Dive Deeper into a Patient Group

 

Each patient segmentation study is as unique as the disease area.

Refine your hypothesis by asking key questions, for example:

 

How can I quantify and understand the best segment for a therapy?

Pharma teams may want to focus their investments on reaching providers and patients that are the most appropriate and have the best chances of uptake.

For example, a brand team may use real-world data to quantify and gain a deeper understanding of the population of rheumatoid arthritis patients who are younger and more likely to use a new therapy, in addition to other key segments – and tailor strategy accordingly.

 

How many meaningful segments require tailored marketing?

Most broad patient populations have diverse demographics, behavioral traits, socio-economic conditions, emotions and lifestyles. Their disease may be the least important characteristic about them.

For example, a team planning a launch strategy for a new NASH treatment would find patient types vary greatly by demographics, socioeconomic factors, insurance type, sites of care, co-morbidities, messaging response, and more.

An advanced sub-segmentation strategy helps a brand quantify the opportunity with key groups, justify a fine-tuned engagement approach, and identify and connect with patients in a more targeted way.

 

Which segments are struggling with treatment compliance and why?

Many factors influence a person’s decision to abandon their treatment plan – from side effects to lifestyle issues to cost to location of care.

For example, a cardiology team can analyze real-world data to quantify and qualify the dynamic issues causing patients to struggle with compliance. And then look at patient characteristics across segmentations, including co-morbidities, burdens of the disease, and location of care.

From there, a pharma team can design supportive outreach and resources to address the real underlying barriers in a far more effective way.

 

 

The Halo Effect of Advanced Segmentation

Asking hard questions and finding meaningful answers takes time, investment and analytical expertise. But drilling deeper benefits every stakeholder in our healthcare ecosystem.

When pharmaceutical teams understand their patients at a much deeper, nuanced level, roadblocks can be addressed and patients can be approached with the level of personalization they expect.

Want to read more?

Download the Full Viewpoint – With Case Study!